N-[(1S)-1-(4-bromophenyl)ethyl]-N'-(3-methyl-5-isoquinolinyl)urea | 581811-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-[(1S)-1-(4-bromophenyl)ethyl]-N'-(3-methyl-5-isoquinolinyl)urea
• 英文别名: 1-[(1S)-1-(4-bromophenyl)ethyl]-3-(3-methylisoquinolin-5-yl)urea
• CAS: 581811-27-0
• 化学式: C₁₉H₁₈BrN₃O
• 分子量: 384.275
• InChiKey: AAFIOYYVAYCSTF-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  54
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (S)-(-)-1-(4-溴苯)乙胺 、 3-methyl-5-isocyanato-isoquinoline 、 5-异氰酸异喹啉 生成 N-[(1S)-1-(4-bromophenyl)ethyl]-N'-(3-methyl-5-isoquinolinyl)urea
  参考文献：
  名称：

  Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

  摘要：

  式(I)1的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热痛敏、尿失禁和膀胱过度活动。

  公开号：

  US20040157849A1

文献信息

• [EN] PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS<br/>[FR] INHIBITEURS DE LA BIOSYNTHESE DE LA PROSTAGLANDINE ENDOPEROXYDE H SYNTHASE
  申请人：ABBOTT LAB

  公开号：WO2000024719A1

  公开（公告）日：2000-05-04

  The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

  本发明描述了式（I）的吡啶酮化合物，它们是环氧合酶（COX）抑制剂，特别是选择性抑制剂环氧合酶-2（COX-2）。COX-2是与炎症有关的诱导型同工酶，而非构成型同工酶环氧合酶-1（COX-1），后者是许多组织（包括胃肠道和肾脏）中重要的“管家”酶。这些化合物对COX-2的选择性最小化了目前市场上非甾体类抗炎药（NSAIDs）所见的不良胃肠道和肾脏副作用。
• Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
  申请人：——

  公开号：US20040209884A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式(I)1的化合物是一种新型的VR1拮抗剂，可用于治疗疼痛、炎性热性过敏、尿失禁和膀胱过度活动。
• Prostaglandin endoperoxide H synthase biosynthesis inhibitors
  申请人：——

  公开号：US20020013318A1

  公开（公告）日：2002-01-31

  The present invention describes pyridazinone compounds of formula I 1 which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

  本发明描述了一类式I1的吡啶嗪化合物，它们是环氧合酶（COX）抑制剂，特别是选择性抑制剂环氧合酶-2（COX-2）。COX-2是与炎症相关的可诱导异构体，而不是重要的“家政”酶在许多组织中，包括胃肠道（GI）和肾脏中的构成性异构体环氧合酶-1（COX-1）。这些化合物对COX-2的选择性最小化了目前市场上非甾体抗炎药（NSAIDs）所见到的不良的GI和肾脏副作用。
• FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
  申请人：LEE CHIH-HUNG

  公开号：US20080214524A1

  公开（公告）日：2008-09-04

  Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  公式（I）的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热痛敏、尿失禁和膀胱过度活动。
• Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
  申请人：Abbott Laboratories

  公开号：US07335678B2

  公开（公告）日：2008-02-26

  Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2, and L are defined in the description.

  式(I)的化合物是新型的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动，其中X1、X2、X3、X4、X5、R5、R6、R7、R8a、R8b、R9、Z1、Z2和L在描述中有定义。